XinZhi Medical

Shanghai XinZhi Medical Technology Co., Ltd. was established on May 18, 2017, with its headquarters located in the Shanghai Zhangjiang Medical Device Industry Base. The company is committed to providing China's leading "intervention without implant" solutions in the cardiovascular and cerebrovascular medical device fields, using balloon and drug-coating technology as a platform.The PTCA drug-eluting balloon catheter independently developed by the company has completed clinical trials and is expected to obtain Class III medical device registration certification in 2021. The PTCA drug-eluting balloon catheter is used for the treatment of coronary artery stenosis and represents an epoch-making advancement in the field of PCI cardiovascular intervention, ushering in a new era of "intervention without implant." The second-generation PTCA drug-eluting balloon catheter, along with intracranial drug balloon catheters and other series of products, will also enter the clinical stage successively. The company’s core R&D and management team comes from leading domestic and international medical device companies, with team members possessing over a decade of experience in cardiovascular medical device R&D. They have successfully developed multiple Class III cardiovascular medical device products, demonstrating extensive experience and strong execution capabilities.